These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21766666)

  • 1. [Aldosterone antagonists and a direct renin inhibitor in the treatment of the metabolic syndrome].
    Tamura N; Nakao K
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():592-6. PubMed ID: 21766666
    [No Abstract]   [Full Text] [Related]  

  • 2. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome.
    Schrier RW; Masoumi A; Elhassan E
    Clin J Am Soc Nephrol; 2010 Jun; 5(6):1132-40. PubMed ID: 20448074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The renin-angiotensin system].
    Hilgers KF
    Urologe A; 2009 Aug; 48(8):925-33; quiz 934-5. PubMed ID: 19669119
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensives.
    Cranwell-Bruce LA
    Medsurg Nurs; 2008 Oct; 17(5):337-41; quiz 342. PubMed ID: 19051983
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.
    Duprez DA
    J Hypertens; 2006 Jun; 24(6):983-91. PubMed ID: 16685192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
    Mahmud A; Feely J
    Am J Hypertens; 2005 Jan; 18(1):50-5. PubMed ID: 15691617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension.
    Gaddam KK; Pratt-Ubunama MN; Calhoun DA
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):353-9. PubMed ID: 16716096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aldosterone antagonists: hypotensive and natriuretic drugs].
    Ulmann A
    Nephrologie; 1985; 6(3):145-6. PubMed ID: 3908958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Can blockade of the renin-angiotensin system be optimised in proteinuric nephropathies?].
    Juárez GF
    Nefrologia; 2008; 28(4):381-4. PubMed ID: 18662145
    [No Abstract]   [Full Text] [Related]  

  • 12. Spironolactone responsive familial hypertension. A potentially high prevalence of mineralocorticoid disease in Oman.
    Woodhouse NJ; Elshafie OT; Mehar A; Johnston WJ; Al-Kaabi JM
    Saudi Med J; 2003 Feb; 24(2):229-31. PubMed ID: 12682699
    [No Abstract]   [Full Text] [Related]  

  • 13. Aldosteronism and hypertension.
    Calhoun DA
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1039-45. PubMed ID: 17699324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone in uremia - beyond blood pressure.
    Ritz E; Koleganova N
    Blood Purif; 2010; 29(2):111-3. PubMed ID: 20093814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome.
    Milionis HJ; Kostapanos MS; Vakalis K; Theodorou I; Bouba I; Kalaitzidis R; Georgiou I; Elisaf MS; Siamopoulos KC
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):181-9. PubMed ID: 18205097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renin-angiotensin-aldosteron system: evolution of views from renin discovery to nowadays. Perspectives of therapeutic block].
    Shestakova MV
    Ter Arkh; 2011; 83(4):71-7. PubMed ID: 21675280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H
    Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New strategy in the treatment of hypertension: inhibition of renin-angiotensin-aldosterone system with renin inhibitor].
    Pál L; Kalina A
    Orv Hetil; 2006 Apr; 147(17):785-9. PubMed ID: 16780186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic possibilities for the inhibition of the renin-angiotensin-aldosterone system].
    Abrahám G; Légrády P
    Orv Hetil; 2003 May; 144(18 Suppl 1):892-5. PubMed ID: 12785232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving understanding of the renin-angiotensin-aldosterone system: pathophysiology and targets for therapeutic intervention.
    Gradman AH
    Am Heart J; 2009 Jun; 157(6 Suppl):S1-6. PubMed ID: 19450719
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.